Around this time last year, Akero was riding high on positive phase 2b data for its candidate non-alcoholic steatohepatitis (NASH ... cirrhosis (F4) due to NASH, a form of non-alcoholic fatty ...

PBC is a chronic, autoimmune disease in which bile ducts in the liver are gradually destroyed, leading to cirrhosis ... placebo plus UDCA achieving that secondary endpoint. The drug was also ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

Nonalcoholic fatty liver disease (NAFLD ... meet criteria for nonalcoholic steatohepatitis (NASH), with its inherent risk for progression to cirrhosis, this still represents an alarmingly large ...

A study from Massachusetts General Hospital has found that growth hormone may help improve liver health in people with ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Weight-Loss Surgery Lowers Risk of Developing Complications of Liver Disease in Patients With Cirrhosis and Obesity Jan. 27, 2025 — A study shows that patients with obesity and fatty liver ...

Separately, drinking damages liver cells trying to metabolize alcohol and can lead to additional fat buildup. The inflammation and scarring caused by excess fat may eventually lead to cirrhosis ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

The American Cancer Society’s estimates for primary liver cancer and intrahepatic bile duct cancer in the United States for 2025 are: About 42,240 new cases (28,220 in men and 14,020 in women) will be ...

The Secondary Suite Incentive Program supports safe housing for all. The incentive program will provide qualifying homeowners with up to $10,000 to build and register a secondary suite. The incentive ...